These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1179 related items for PubMed ID: 17576937

  • 1. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
    Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Jahreis A.
    Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
    [Abstract] [Full Text] [Related]

  • 2. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
    van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, Leigheb G, Camacho FM, Forsea D, Zang C, Boussuge MP, Paolozzi L, Wajdula J.
    Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
    [Abstract] [Full Text] [Related]

  • 3. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis.
    Elewski B, Leonardi C, Gottlieb AB, Strober BE, Simiens MA, Dunn M, Jahreis A.
    Br J Dermatol; 2007 Jan; 156(1):138-42. PubMed ID: 17199580
    [Abstract] [Full Text] [Related]

  • 4. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
    Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, Jahreis A.
    Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657
    [Abstract] [Full Text] [Related]

  • 5. Etanercept treatment for children and adolescents with plaque psoriasis.
    Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, Hebert AA, Eichenfield LF, Patel V, Creamer K, Jahreis A, Etanercept Pediatric Psoriasis Study Group.
    N Engl J Med; 2008 Jan 17; 358(3):241-51. PubMed ID: 18199863
    [Abstract] [Full Text] [Related]

  • 6. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
    Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L, Etanercept Psoriasis Study Group.
    Br J Dermatol; 2005 Jun 17; 152(6):1304-12. PubMed ID: 15948997
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis.
    Landells I, Paller AS, Pariser D, Kricorian G, Foehl J, Molta C, Freundlich B.
    Eur J Dermatol; 2010 Jun 17; 20(3):323-8. PubMed ID: 20185386
    [Abstract] [Full Text] [Related]

  • 8. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis.
    Reich K, Segaert S, Van de Kerkhof P, Durian C, Boussuge MP, Paolozzi L, Wajdula J, Boggs R.
    Dermatology; 2009 Jun 17; 219(3):239-49. PubMed ID: 19752505
    [Abstract] [Full Text] [Related]

  • 9. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.
    Moore A, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia HA, Stevens SR.
    J Am Acad Dermatol; 2007 Apr 17; 56(4):598-603. PubMed ID: 17113190
    [Abstract] [Full Text] [Related]

  • 10. A randomized trial of etanercept as monotherapy for psoriasis.
    Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, Gaspari AA, Ling M, Weinstein GD, Nayak A, Gordon KB, Zitnik R.
    Arch Dermatol; 2003 Dec 17; 139(12):1627-32; discussion 1632. PubMed ID: 14676082
    [Abstract] [Full Text] [Related]

  • 11. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
    Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J.
    Arthritis Rheum; 2003 Jun 17; 48(6):1667-75. PubMed ID: 12794835
    [Abstract] [Full Text] [Related]

  • 12. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study.
    Leonardi C, Strober B, Gottlieb AB, Elewski BE, Ortonne JP, van de Kerkhof P, Chiou CF, Dunn M, Jahreis A.
    J Drugs Dermatol; 2010 Aug 17; 9(8):928-37. PubMed ID: 20684143
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
    Gordon K, Korman N, Frankel E, Wang H, Jahreis A, Zitnik R, Chang T.
    J Am Acad Dermatol; 2006 Mar 17; 54(3 Suppl 2):S101-11. PubMed ID: 16488320
    [Abstract] [Full Text] [Related]

  • 14. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, Burge DJ.
    Arthritis Rheum; 2004 Feb 17; 50(2):353-63. PubMed ID: 14872476
    [Abstract] [Full Text] [Related]

  • 15. Long-term etanercept in pediatric patients with plaque psoriasis.
    Paller AS, Siegfried EC, Eichenfield LF, Pariser D, Langley RG, Creamer K, Kricorian G.
    J Am Acad Dermatol; 2010 Nov 17; 63(5):762-8. PubMed ID: 20605256
    [Abstract] [Full Text] [Related]

  • 16. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial.
    Gisondi P, Del Giglio M, Cotena C, Girolomoni G.
    Br J Dermatol; 2008 Jun 17; 158(6):1345-9. PubMed ID: 18410408
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A, Esposito M, Costanzo A, Chimenti S.
    Am J Clin Dermatol; 2009 Jun 17; 10(5):319-24. PubMed ID: 19658444
    [Abstract] [Full Text] [Related]

  • 18. Two years of experience with etanercept in recalcitrant psoriasis.
    Ahmad K, Rogers S.
    Br J Dermatol; 2007 May 17; 156(5):1010-4. PubMed ID: 17408393
    [Abstract] [Full Text] [Related]

  • 19. Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis: results of a pilot experience (power study).
    Cassano N, Loconsole F, Galluccio A, Miracapillo A, Pezza M, Vena GA.
    Int J Immunopathol Pharmacol; 2006 May 17; 19(1):225-9. PubMed ID: 16569361
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis.
    Davis JC, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ, Fleischmann RM, Inman RD, Ni L, Lin SL, Tsuji WH.
    Ann Rheum Dis; 2008 Mar 17; 67(3):346-52. PubMed ID: 17967833
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.